VEA
ARRY

Virtus ETF Advisers’s Array Biopharma Inc ARRY Stock Holding History

Virtus ETF Advisers’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-27,357
Closed -$1.27M – 460
2019
Q2 		$1.27M Sell
27,357
-21,565
-44% -$605K 0.27% 149
2019
Q1 		$1.19M Buy
48,922
+10,443
+27% +$217K 2.54% 3
2018
Q4 		$548K Buy
38,479
+12,195
+46% +$185K 0.09% 69
2018
Q3 		$400K Sell
26,284
-18,803
-42% -$288K 0.04% 165
2018
Q2 		$757K Sell
45,087
-23,676
-34% -$377K 0.67% 65
2018
Q1 		$1.12M Buy
68,763
+36,645
+114% +$587K 0.97% 24
2017
Q4 		$411K Sell
32,118
-10,118
-24% -$115K 0.52% 49
2017
Q3 		$520K Buy
42,236
+3,863
+10% +$35.9K 0.07% 84
2017
Q2 		$321K Buy
38,373
+6,350
+20% +$51.9K 0.05% 105
2017
Q1 		$286K Buy
32,023
+3,070
+11% +$32.7K 0.05% 142
2016
Q4 		$254K Sell
28,953
-46,147
-61% -$340K 0.08% 137
2016
Q3 		$507K Hold
75,100
– – 0.25% 71
2016
Q2 		$267K Buy
75,100
+8,724
+13% +$28.4K 0.2% 73
2016
Q1 		$196K Buy
+66,376
New +$199K 0.27% 87

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Virtus ETF Advisers's ARRY Position: Q3 2019 in Review

Virtus ETF Advisers sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 27,357 shares — an estimated $1.27M sold.

Virtus ETF Advisers first reported a position in ARRY in Q1 2016 and held it in 14 quarters. The position peaked at $1.27M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Virtus ETF Advisers reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Virtus ETF Advisers sold 27,357 Array Biopharma Inc shares in Q3 2019, an estimated $1.27M.
  • Virtus ETF Advisers first reported a position in Array Biopharma Inc in Q1 2016 and held it in 14 quarters.
  • Virtus ETF Advisers's Array Biopharma Inc position peaked at $1.27M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Virtus ETF Advisers's 13F filing for Q3 2019, filed 12 Nov 2019.